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Enantioselective Total Synthesis of ()-Finerenone Using Asymmetric
Transfer Hydrogenation
Andreas Lerchen+, Narasimhulu Gandhamsetty+, Elliot H. E. Farrar, Nils Winter,
Johannes Platzek, Matthew N. Grayson,* and Varinder K. Aggarwal*
Abstract: ()-Finerenone is a nonsteroidal mineralocorticoid
receptor antagonist currently in phase III clinical trials for the
treatment of chronic kidney disease in type 2 diabetes. It
contains an unusual dihydronaphthyridine core. We report a
6-step synthesis of ()-finerenone, which features an enantio-
selective partial transfer hydrogenation of a naphthyridine
using a chiral phosphoric acid catalyst with a Hantzsch ester.
The process is complicated by the fact that the naphthyridine
exists as a mixture of two atropisomers that react at different
rates and with different selectivities. The intrinsic kinetic
resolution was converted into a kinetic dynamic resolution at
elevated temperature, which enabled us to obtain ()-finer-
enone in both high yield and high enantioselectivity. DFT
calculations have revealed the origin of selectivity.
Mortality rates due to heart failure can be markedly
reduced by treatment with certain steroids (spironolactone
(1) and eplerenone (2)) which block the mineralocorticoid
receptor (MR) (Figure 1).[1] However, their clinical use is
limited due to the significant side effects they can cause for
example, hyperkalemia and worsening of kidney function[2]
and so new MR antagonists are required.[3] As an alternative,
it has been reported that 1,4-dihydropyridines (DHPs),
a compound class known for its Ca2+ channel modulating
activity,[4] can act as MR antagonists in vitro.[5] Through
a DHP-based screening program, Bayer identified finerenone
()-3 (BAY 94-8862) as a novel, highly potent (IC50 18 nM),
nonsteroidal selective mineralocorticoid receptor antago-
nist.[6] It is currently in phase III clinical trials for the
treatment of chronic kidney disease in type 2 diabetes.
Finerenone is presently prepared in a racemic form and the
active (S)-enantiomer is separated by chiral column chroma-
tography. Although the unwanted (R)-enantiomer can be
recycled back to the racemate in two steps,[7] this overall
process is wasteful and time-consuming, especially when
conducted on the scales currently required for phase III
clinical trials (> 1000 kg). Because of these significant short
comings, we were interested in developing an enantioselective
synthesis of this challenging molecule.
There are no asymmetric methods to dihydronaphthyr-
idines, the core structure of finerenone ()-3, but there are
two general methods available to the structurally related
dihydroquinolines.[8–10] These are (i) formal [4+2]-cyclization
reaction between an ortho-quinone methide imine precursor
4 and b-keto-amide 5 in the presence of a chiral phosphoric
acid catalyst (Figure 2a)[8] and (ii) site-selective partial trans-
fer hydrogenation of a naphthyridine 6 using a Hantzsch ester
derivative, again in the presence of a chiral phosphoric acid
catalyst (Figure 2b).[9, 11]
We began our studies investigating the formal [4+2]-
cyclization approach for which we required the amino alcohol
4 (Figure 2a). Starting from commercially available pyridone
8, selective O-alkylation in the presence of Ag2CO3
[12]
followed by N-protection using pivaloyl chloride gave amide
9 in 52% yield over two steps. Directed lithiation of 9 and
subsequent trapping with aldehyde 10 led to alcohol 11 in
91% yield.[13] A brief investigation of this step revealed that
a solvent mixture of THF/Et2O was necessary together with
TMEDA to obtain optimum results. Acid catalyzed depro-
tection using HCl gave amino alcohol (4) in 65% yield
(Scheme 1a).[14] With the amino alcohol (4) in hand, we
investigated the enantioselective [4+2]-cyclization with ace-
toacetamide 5 using a broad array of chiral phosphoric acids
as catalyst (Scheme 1, see the Supporting Information for
further details). However, despite an extensive screen of
conditions and catalysts, the best result we obtained was 15%
ee using 10 mol% (R)-TRIP.
Figure 1. Spironolactone, eplerenone, and finerenone as representative
mineralocorticoid receptor antagonists.
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As an alternative, we explored the partial transfer hydro-
genation reaction for which we required naphthyridine 6
(Figure 2b). This compound was obtained from alcohol 4 by
an acid catalyzed [4+2]-cyclization with acetoacetamide 5
followed by oxidation with nitric acid in a one pot process in
57% yield (Scheme 1).[15] With the naphthyridine 6 in hand,
we first explored a range of chiral phosphoric acids (5 mol%)
for the partial transfer hydrogenation in combination with the
Hantzsch ester 7 (Scheme 2a). Although only 21% ee was
obtained using (R)-TRIP (12 a) as chiral catalyst (entry 1),
other chiral phosphoric acids performed better with the
anthracenyl moiety 12d proving optimum, giving (+)-3 in
42% yield and 94% ee after 16 hours. Interestingly, in related
reductions of quinolines to dihydroquinolines, 12d gave
essentially racemic products but 12 a/b gave high enantiose-
lectivity.[9] In screening other conditions, we found that the
enantioselectivity was remarkably insensitive to solvent
effects giving > 90 % ee for all solvents tested (see the
Supporting Information for further details). However,
attempts to push the reaction to completion by extending
reaction time, changing the concentration, adding molecular
sieves or using an excess of catalyst came to no avail; the
reaction slowed down considerably at around 50% yield
(Scheme 2a). This prompted us to re-isolate the starting
material and to explore its properties further. Chiral SFC
analysis revealed that the starting material existed in two
atropisomeric forms and that the recovered starting material
was now enriched in one of the atropisomers, with the ratio
increasing with increasing conversion (Scheme 2 a). We were
able to determine the relative rate of reaction of the two
atropisomers by determining the extent of conversion at short
reaction times (4 h, 40 8C, 18% conversion; see the Support-
ing Information for further details). This revealed that
the (R)-atropisomer reacted  30 times faster with the
(R)-catalyst than the (S)-atropisomer.
The thermal stability of the atropisomers was subse-
quently explored (Scheme 2b). Heating a 91.4:8.6 ratio of
atropisomers at various temperatures for 24 hours showed
that racemization was just beginning at 40 8C but was
essentially complete at 100 8C.
In order to determine the enantioselectivity in the
reduction of the two atropisomers, they were separated by
semi-prep chiral HPLC[16] and reacted with the (S)-catalyst at
40 8C for 24 hours. In the case of the (S)-atropisomer, a 42%
yield of 3 was obtained with remarkably high enantioselec-
tivity (> 99:1 e.r., matched) but in the case of the
(R)-atropisomer, 3 was obtained in just 5 % yield and 61:39
e.r. (mismatched) (Scheme 2c).
Since the two atropisomers reacted with markedly differ-
ent selectivities, we needed to perform a dynamic kinetic
resolution where the slow reacting and non-selective atrop-
isomer isomerized into the fast reacting and selective
atropisomer before it reacted. We reasoned that at elevated
temperature, the unimolecular racemization process should
increase in rate faster than the reduction process which
required 3 molecules to come together, due to entropy. We
therefore carried out reactions at increasing temperatures
(60–100 8C). In the mismatched case [(R)-atropisomer] we
were pleased to observe both increasing yields, and increasing
enantioselectivity, validating our hypothesis (Scheme 2c,
entries 2–4). It is unusual to observe higher enantioselectivity
Figure 2. Two strategies for the enantioselective synthesis of finere-
none.
Scheme 1. Isolated yields are given. a) Ethyl iodide (2.0 equiv), Ag2CO3
(2.2 equiv), toluene, 115 8C, 16 hours. b) PivCl (1.5 equiv), NEt3
(2.0 equiv), CH2Cl2, r.t. 48 hours. c) TMEDA (2.5 equiv), nBuLi
(2.5 equiv), aldehyde (2.5 equiv), Et2O/THF, 78 8C to r.t. d) Conc.
HCl, dioxane/H2O, 83 8C, 3 hours. e) (R)-TRIP (10 mol%), acetoaceta-
mide (3.0 equiv), 4  molecular sieves, toluene, 110 8C, 24 hours; ee of
the product was determined by chiral SFC. f) DPP (20 mol%), acetoa-
cetamide (3.0 equiv), 4  molecular sieves, toluene, 110 8C, 24 hours.
g) HNO3 (1.5 equiv), nBuOH, 100 8C, 3 hours. DPP=diphenyl phos-
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at higher temperatures, but it occurs here because of the
increased rate of isomerization of the atropisomers.
Interestingly, reaction of the matched (S)-atropisomer at
100 8C for 24 hours leads to an increase in yield with only
a marginal decrease in enantioselectivity (Scheme 2c,
entries 5,6). After reaction at 100 8C for 24 hours, the
recovered starting material was racemic indicating that
a dynamic kinetic resolution was occurring (Scheme 2c,
entries 4,6).
This detailed optimization and mechanistic analysis
revealed that elevated temperature should provide both
high yield and high enantioselectivity. Simply reacting the
racemic mixture of atropisomers of 6 at 100 8C for 24 h gave
finerenone ()-3 in 82% yield with 94:6 e.r. (Scheme 2d). On
 2 mmol scale similar e.r. but a slight reduction in yield was
observed.
In order to understand the origin of the selectivity issues
encountered we have carried out DFT[17, 18] calculations
(Gaussian16 RevisionA.03,[19] see the Supporting Informa-
tion for further details) and determined the TSs for reaction
of both atropisomers. Note that the Hantzsch ester was
simplified to a methyl ester and the ethoxy group on 6 was
replaced by a methoxy group. By taking a Boltzmann
weighting at 313 K over all conformers within 5 kcalmol1
of the lowest in free energy, an ee of 98% at 40 8C was
predicted, in close agreement with the experimental value of
94% (Scheme 2a). As summarized in Scheme 2c, our calcu-
lations also match the observed atropisomer selectivities
exceptionally closely.
The mechanism of the reaction involves protonation of
the naphthyridine ring by the chiral phosphoric acid with
simultaneous hydrogen bonding to the Hantzsch ester
(Scheme 3). In this assembly concomitant hydride and
proton transfer occurs to give the dihydronaphthyridine.
The most favored arrangement places the bulk of
the naphthyridine ring in open space leading to the major
enantiomer (Scheme 3a). In this TS assembly the
(R)-atropisomer is expected to hinder the approach of the
incoming Hantzsch ester, accounting for its slow rate of
reaction, whilst addition to the (S)-atropisomer is un-
impeded. In the TSs leading to the opposite enantiomer
(Scheme 3b) the catalyst is rotated through 908, avoiding any
steric clash with the naphthyridine ring but at the expense of
the strength and directionality of the hydrogen bonds
between the catalyst and substrate.
In conclusion, we have developed a short 6-step enantio-
selective synthesis of finerenone, a mineralocorticoid recep-
tor antagonist candidate in phase III clinical trials. The key
step in the synthesis was the partial transfer hydrogenation of
naphthyridine 6, which gave finerenone ()-3 in high yield
and with high enantiomeric excess. A detailed mechanistic
analysis revealed that naphthyridine 6 existed in two atrop-
Scheme 2. Isolated yields are given. The e.r. of (3) and (6) was determined by chiral SFC. a) Catalyst screening for partial transfer hydrogenation.
b) Investigation of interconversion of atropisomers of starting material with temperature. c) Determination of the enantioselectivity in the
reduction of the two separated atropisomers at different temperatures and calculations of the energy barriers. Computed ratios obtained by taking
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isomeric forms that reacted at different rates and with
different selectivities, leading to a kinetic resolution. The
intrinsic kinetic resolution was transformed into a kinetic
dynamic resolution at elevated temperature, enabling
()-finerenone to be obtained in both high yield and high
enantioselectivity. A model to account for the stereocontrol
has been included.
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